Relation of CDC42, Th1, Th2, and Th17 cells with cognitive function decline in Alzheimer's disease
Authors:
Open Access
- 17 August 2022
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 9 (9) , 1428-1436
Abstract
Objective: Cell division cycle 42 (CDC42) regulates neurite outgrowth, neurotransmitter, and T help (Th) cell‐mediated neuroinflammation, while its clinical implication in Alzheimer's disease (AD) is not clear. The present study aimed to investigate the correlation of CDC42 with Th1, Th2, and Th17 cells, as well as CDC42’ longitudinal change and relation to cognitive function decline in AD patients.Methods: 150 AD patients were enrolled, then their blood Th1, Th2, and Th17 cells were quantified by flow cytometry at baseline; CDC42 was detected by RT‐qPCR and MMSE score was assessed at baseline and during 3‐year follow‐up. Meanwhile, CDC42, Th1, Th2, and Th17 cells were quantified in 30 Parkinson's disease (PD) patients and 30 healthy controls (HCs).Results: CDC42 (p < 0.001) and Th2 cells (p < 0.001) were lowest in AD patients, followed by PD patients, highest in HCs; but Th1 cells (p = 0.001) and Th17 cells (p < 0.001) showed opposite trends. CDC42 was not related to Th1 cells (p = 0.134), positively correlated with Th2 cells (p = 0.023) and MMSE (p < 0.001), while negatively associated with Th17 cells (p < 0.001) in AD patients. CDC42 was only related to Th17 cells (p = 0.048) and MMSE (p = 0.048) in PD patients; and it was not linked with Th1, Th2, Th17 cells, or MMSE in HCs (all p > 0.05). During a 3‐year follow‐up, CDC42 was gradually declined in AD patients (p < 0.001), its decline was positively correlated with MMSE decline at 1 year (p = 0.004), 2 years (p = 0.005), and 3 years (p = 0.026).Interpretation: CDC42 might have the potency to serve as a biomarker for estimating AD risk and progression.Keywords
This publication has 36 references indexed in Scilit:
- Integrated Analysis and Identification of Novel Biomarkers in Parkinson’s DiseaseFrontiers in Aging Neuroscience, 2018
- Reciprocal Regulation of Glycolysis-Driven Th17 Pathogenicity and Regulatory T Cell Stability by Cdc42The Journal of Immunology, 2018
- Altered Expression of Circulating Cdc42 in Frontotemporal Lobar DegenerationJournal of Alzheimer’s Disease, 2018
- Rho GTPases as therapeutic targets in Alzheimer’s diseaseAlzheimer's Research & Therapy, 2017
- Rpph1 Upregulates CDC42 Expression and Promotes Hippocampal Neuron Dendritic Spine Formation by Competing with miR-330-5pFrontiers in Molecular Neuroscience, 2017
- Cdc42: An important regulator of neuronal morphologyThe International Journal of Biochemistry & Cell Biology, 2012
- Distinct Roles of Cdc42 in Thymopoiesis and Effector and Memory T Cell DifferentiationPLOS ONE, 2011
- Regulation of axotomy‐induced dopaminergic neuron death and c‐Jun phosphorylation by targeted inhibition of cdc42 or mixed lineage kinaseJournal of Neurochemistry, 2005
- Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's β-amyloid1–42Journal of Neuroimmunology, 2002
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984